Appendix Table D11. Efficacy of topiramate on migraine prevention (results from a single RCT with medium risk of bias)8

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Drug**  **Dose** | **Definition of the outcome** | **Events/randomized with drug** | **Events/randomized with placebo** | **Relative risk**  **(95% CI)** | **Absolute risk difference (95% CI)** |
| Topiramate 50 mg/day at week 3, titrated to a max dose of 200 mg/day (2-3kg mg/kg/day) | ≥75% reduction in monthly migraine days | 36/112 | 7/50 | **2.3 (1.1 to 4.8)** | **0.18 (0.05 to 0.31)** |
| ≥75% reduction in monthly migraine days during the last 28 days of treatment | 57/112 | 15/50 | **1.7 (1.1 to 2.7)** | **0.21 (0.05 to 0.37)** |

Bold - significant difference at 95% confidence level when 95% CI of absolute risk difference do not include 0